
Mithrl, the San Francisco startup behind a Scientific Decision Engine for drug discovery, just raised a $20 million Series A led by Obvious Ventures. Co-founder Vivek Adarsh came out of NVIDIA's CUDA compiler team, and his pitch is triage: AI has made drug hypotheses cheap, lab experiments are still expensive, so Mithrl's biomedical world model helps decide which ideas are worth testing. Here's how it works, who it's up against, and why patents are the number Adarsh cares about most.
Chapters
0:00 Mithrl in 30 seconds
0:24 Why Mithrl exists
1:01 The $20M Series A
1:59 Ideas got cheap, testing didn't
3:20 The biomedical world model
5:41 Benchmarks, customers and patents
8:42 Brian's Take
Startup Bios is the show about the newest startups coming out of stealth, hosted by Brian McCullough. Like and subscribe, and get the audio version on the Startup Bios podcast wherever you get your podcasts.
Hosted on Acast. See acast.com/privacy for more information.
D'autres épisodes de "Startup Bios"



Ne ratez aucun épisode de “Startup Bios” et abonnez-vous gratuitement à ce podcast dans l'application GetPodcast.




